1. Silk-elastinlike protein polymers enhance the efficacy of a therapeutic glycosaminoglycan for prophylactic treatment of radiation-induced proctitis
- Author
-
Hamidreza Ghandehari, Wanjian Jia, Mark Martin Jensen, Kyle J. Isaacson, Siam Oottamasathien, Austin Schults, Joseph Cappello, and Glenn D. Prestwich
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,Pain ,Pharmaceutical Science ,Rectum ,Enema ,02 engineering and technology ,Pharmacology ,Radiation enteropathy ,Mice ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Prostate ,Hyaluronic acid ,medicine ,Animals ,Proctitis ,Adverse effect ,Glycosaminoglycans ,Behavior, Animal ,business.industry ,X-Rays ,Proteins ,Hydrogels ,021001 nanoscience & nanotechnology ,medicine.disease ,3. Good health ,Surgery ,Radiation therapy ,Drug Liberation ,Radiation Injuries, Experimental ,medicine.anatomical_structure ,chemistry ,030220 oncology & carcinogenesis ,Female ,Rheology ,0210 nano-technology ,business - Abstract
Radiation-induced proctitis (RIP) is the most common clinical adverse effect for patients receiving radiotherapy as part of the standard course of treatment for ovarian, prostate, colon, and bladder cancers. RIP limits radiation dosage, interrupts treatment, and lowers patients' quality of life. A prophylactic treatment that protects the gastrointestinal tract from deleterious effects of radiotherapy will significantly improve patient quality of life and may allow for higher and more regular doses of radiation therapy. Semi-synthetic glycosaminoglycan (GAG), generated from the sulfation of hyaluronic acid, are anti-inflammatory but have difficulty achieving therapeutic levels in many tissues. To enhance the delivery of GAG, we created an in situ gelling rectal delivery system using silk-elastinlike protein polymers (SELPs). Using solutions of SELP 815K (which contains 6 repeats of blocks comprised of 8 silk-like units, 15 elastin-like units, and 1 lysine-substituted elastin-like unit) with GAG GM-0111, we created an injectable delivery platform that transitioned in
- Published
- 2017
- Full Text
- View/download PDF